Description

Balchem Corporation: Europe’s Choline Reset Creates a Clear Runway for Feed-Grade Growth and Market Share Expansion!

Balchem Corporation concluded 2025 with a robust financial performance, characterized by record sales and earnings. The company’s revenue for the year exceeded $1 billion for the first time, representing an 8.8% rise compared to the prior year. This growth was evenly reflected across all three of its business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The company’s strategic focus and effective execution were highlighted through a 9.8% increase in adjusted EBITDA and a net earnings growth of 14.4%. The fourth quarter of 2025 further exemplified Balchem’s strong performance, with a 9.8% increase in consolidated revenue to $264 million. GAAP earnings from operations rose by 10.2%, and adjusted EBITDA increased by 8.1%, reflecting the company’s continuous operational efficiency. The Human Nutrition & Health segment particularly stood out with a 12.7% sales growth, driven by robust demand for minerals, vitamins, and food ingredients.